This study demonstrates that NGS-MSI is noninferior to IHC-MMR and can identify MSI-H tumors that IHC-MMR is unable to detect and conversely IHC-MMR can identify MMRd tumors that NGS-MSI misses. This ...
Red arrows indicate the DNA repair pathways that are known to aid bacterial survival as persisters and gamblers in the presence of fluoroquinolones. Blue color arrow indicates downregulation, while ...
Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing The following ...
Please provide your email address to receive an email when new articles are posted on . Patients with stage III deficient mismatch repair colon cancer derived significant benefit from the addition of ...
The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.
A new UCLA Health study has discovered in mouse models that genes associated with repairing mismatched DNA are critical in eliciting damages to neurons that are most vulnerable in Huntington's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results